Precigen (PGEN) Is Up 16.3% After Papsimios-Fueled Return To Profitability And Broad Payer Coverage
Precigen (PGEN) reported a significant return to profitability in Q2 2026, driven by strong revenue and net income largely attributed to the rapid uptake of Papsimios. The company's profitability and broad payer coverage, along with seven-year FDA market exclusivity for Papsimios, strengthen its investment …